Aug 11, 2014 ... FOR THE DISTRICT OF DELAWARE. In re: ) Chapter 11. ) VASO ACTIVE
PHARMACEUTICALS, INC., ). ) Case No. 10-10855 (CSS). Debtors.
Aug 17, 2004 ... Litigation Release No. 18834 / August 17, 2004. SEC Files Settled Action
Charging Vaso Active Pharmaceuticals, Inc. and its President and ...
Beverly Enterprises - Arkansas, Inc., et al. and Vera Cooney and Eula Mae Allen,
et al., v. Beverly ...... In re Vaso Active Pharmaceuticals Securities Litigation.
May 7, 2013 ... Vasoactive intestinal peptide (VIP) exerts immune-modulatory actions mainly ....
B according the protocol (Phoenix Pharmaceuticals Inc., Karlsruhe, Germany)
and .... It is likely that receptor internalization as described by Langlet et al.,  is
... As suggested previoulsy , recycling and re-organization of ....
Jul 7, 2009 ... heart failure while lacking the vasoactive properties of BNP. These findings ...
Genome-wide analyses have revealed the prevalence of al- ternative .... Pan et al
. PNAS. July 7 ... As alternative splicing usually affects coding re- .... BNP (hBNP,
Phoenix Pharmaceuticals, Inc.) or ASBNP.1 (final concentration.
Sep 22, 2014 ... A vasoactive role for relaxin is supported by our recent data that .... ml TriReagent
(Ambion Inc., Scoresbury, VIC, Australia) and total RNA was ..... This could have
been due to differences in compositional remodeling or re-arrangement of .... 9.
van Drongelen J, van Koppen A, Pertijs J, Gooi J, Parry L, et al.
Abstract. In the search for mechanisms of obesity-mediated vascular pathology,
attention has been focused on the role played by adipose tissue, ...
Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in
Humans In Vivo .... Then, 0.5% albumin (albumin [human], U.S. Pharmacopeia;
Plasbumin-25; Bayer, Pharmaceutical Division, Elkhart, IN) .... (SPSS 11.5 for
Windows; SPSS Inc., Chicago, IL). ..... Takiyyuddin MA, Parmer RJ, Kailasam MT,
Polyurethane catheter tubing (Micro-Renathane, Braintree Scientific Inc., ... was
performed with the Phoenix OT kit (Phoenix Pharmaceuticals Inc., Belmont, CA, ...
per animal for the intensity of VIP immunoreactivity as described by Turgeon et al.
..... Arey BJ, Freeman ME 1990 Oxytocin, vasoactive-intestinal peptide, and ...
You're seeing our new article page and we'd like your opinion, send feedback ...
Cite this article as: Kőhidai, L., Tóth, K., Samotik, P. et al. .... Peptides tested were
human adrenomedullin1-52, PAMP and CGRP (Phoenix Pharmaceuticals Inc.).